Skip to main content
DrugPrice

Growth Disorders Drug Costs With Medicare

Compare 6 growth disorders drug prices under Medicare Part D, averaging $2,386.33 per claim. Prices range from $1,887.00 (Omnitrope) to $3,441.00 (Skytrofa) per prescription. 6 of 6 drugs have FDA-approved generics that cost 30-80% less.

Key Facts: Growth Disorders Drug Costs

Cheapest drug
Omnitrope ($1,887.00)
Most expensive
Skytrofa ($3,441.00)
Medicare Part D avg
$2,386.33/claim
Generics available
6 of 6
Total Medicare spend
$2.0B/yr
Brand-only drugs
0

Source: CMS Medicare Part D Spending, latest reporting year. Costs reflect plan-paid amounts, not patient out-of-pocket.

Growth Disorders Drug Price Comparison

All 6 growth disorders drugs tracked in Medicare Part D, sorted from cheapest to most expensive. Click any drug for Medicare coverage details, generic timelines, and savings options.

DrugGeneric NameMedicare Avg/ClaimGeneric Available?
OmnitropeSomatropin (biosimilar)$1,887.00Yes
SogroyaSomapacitan$2,070.00Yes
NorditropinSomatropin$2,286.00Yes
GenotropinSomatropin$2,303.00Yes
HumatropeSomatropin$2,331.00Yes
SkytrofaLonapegsomatropin$3,441.00Yes

Medicare Part D Coverage for Growth Disorders Drugs

All 6 growth disorders drugs in this comparison are dispensed under Medicare Part D. Total Medicare spending reached $2.0B in the latest reporting year, averaging $2,386.33 per prescription fill.

Your out-of-pocket cost depends on three factors: (1) your plan's formulary tier — generics typically land on Tier 1 ($0-$10 copay), preferred brands on Tier 2 ($30-$50), and specialty drugs on Tier 4-5 (often 25-33% coinsurance); (2) your deductible status — most plans require you to meet up to a $590 deductible before copays apply; (3) the coverage phase — initial coverage, coverage gap, or catastrophic. As of 2025, Medicare Part D caps total annual out-of-pocket at $2,000 under the Inflation Reduction Act.

The 6 drugs with generic availability are usually the most cost-effective starting point — ask your prescriber whether a generic substitution is clinically appropriate.

Drug costs vary dramatically within this category. Skytrofa (Lonapegsomatropin) at $3,441.00 per claim is 2x more expensive than Omnitrope (Somatropin (biosimilar)) at $1,887.00 — yet both treat growth disorders. Therapeutic substitution within the same drug class is often the single biggest savings lever, and it requires only a prescriber conversation, not a plan change.

Frequently Asked Questions

Medicare Part D pays an average of $2,386.33 per claim for growth disorders medications across 6 tracked drugs. Patient out-of-pocket costs depend on your plan's formulary tier, deductible, and whether you've reached the catastrophic coverage phase. Most growth disorders drugs fall on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) of standard Medicare Part D formularies.

The least expensive growth disorders medication is Omnitrope (Somatropin (biosimilar)) at $1,887.00 per Medicare Part D claim. A generic version is FDA-approved and available — ask your pharmacist about substitution to lower copays further.

Yes. All 6 growth disorders drugs tracked here appear in Medicare Part D claims data, meaning they are dispensed under Part D plans. Coverage details — formulary tier, prior authorization requirements, step therapy — vary by plan. Check your plan's formulary or call 1-800-MEDICARE before filling.

Yes, 6 of 6 growth disorders drugs have FDA-approved generic alternatives. Generics contain the same active ingredient and meet bioequivalence standards, but typically cost 30-80% less. On Medicare Part D, generics usually fall on Tier 1 with the lowest copay.

Three primary strategies: (1) Switch to a generic if available — Tier 1 generics typically cost under $10 per fill on Medicare Part D; (2) Use manufacturer copay assistance for brand-name drugs (commercial insurance only — Medicare beneficiaries can apply for patient assistance foundations like NeedyMeds or the PAN Foundation); (3) Compare cash prices using GoodRx, SingleCare, or Mark Cuban's Cost Plus Drugs — sometimes cash pay beats your Part D copay. Talk to your doctor about therapeutic alternatives in the same drug class.

Cost per claim is the average plan-paid amount per prescription fill under Medicare Part D. Patient out-of-pocket varies by formulary tier and deductible status. Generic availability is based on FDA Orange Book data.

Source: CMS Medicare Part D Spending, 2026.